cancer
cell
depend
capdepend
translat
normal
tissu
explain
emerg
protein
involv
capdepend
translat
target
potenti
anticanc
drug
capdepend
translat
start
bind
mrna
cap
domain
review
present
structur
function
also
expos
use
therapeut
target
cancer
discov
consid
isol
protein
belong
known
protein
famili
research
last
decad
show
eukaryot
sever
member
famili
joshi
et
al
identifi
sequenc
analysi
famili
member
speci
three
isoform
present
mammal
joshi
cameron
jagu
protein
famili
bind
methylguanosin
mrna
cap
ligand
joshi
et
al
robalino
et
al
rosettani
et
al
give
differ
physiolog
function
hernandez
vazquezpianzola
suggest
organ
one
member
famili
express
interven
translat
member
function
develop
translat
repress
specif
mrna
nuclear
transport
hypothesi
confirm
sinc
isoform
thought
involv
mani
function
spermatogenesi
oogenesi
age
function
amiri
et
al
dinkova
et
al
evsikov
marin
de
evsikova
minshal
et
al
syntichaki
troulinaki
tavernaraki
capdepend
translat
start
bind
mrna
cap
domain
cancer
cell
depend
capdepend
translat
normal
tissu
jia
et
al
review
expos
structur
function
expos
use
anticanc
target
structur
express
structur
primari
structur
fig
highli
conserv
eukaryot
import
role
play
cell
ntermin
end
sequenc
variabl
differ
organ
end
seem
involv
initi
translat
function
tertiari
structur
character
mice
men
yeast
wheat
monzingo
et
al
tomoo
et
al
structur
compos
eight
antiparallel
strand
three
helic
convex
side
fig
bind
mrna
cap
allow
translat
initi
tridimension
structur
interact
cap
analog
identifi
allow
identifi
interact
site
gross
et
al
niedzwiecka
et
al
tomoo
et
al
cap
interact
happen
hydrophob
pocket
concav
side
due
interact
two
highli
conserv
tryptophan
residu
mice
fig
interact
stabil
three
hydrogen
bond
interact
partner
protein
involv
translat
regul
bind
protein
take
place
hydrophob
region
convex
side
involv
two
conserv
tryptophan
residu
mice
fig
protein
interact
bond
pattern
consensu
sequenc
x
x
amino
acid
hydrophob
residu
bind
caus
conform
chang
increas
affin
cap
niedzwiecka
et
al
von
der
haar
ball
mccarthi
pml
protein
promyelocyt
leukemia
protein
viral
protein
z
vpz
repres
second
class
regul
interven
mrna
nuclear
export
function
protein
bind
convex
side
use
ring
domain
contrast
bond
decreas
affin
cap
cohen
et
al
kentsi
et
al
volpon
et
al
structur
studi
show
differ
conform
differ
ligand
bind
affin
depend
whether
bind
cap
niedzwiecka
et
al
niedzwiecka
darzynkiewicz
stolarski
volpon
et
al
tomoo
et
al
cell
tissu
growth
depend
protein
synthesi
express
significantli
higher
human
malign
tissu
normal
tissu
cell
viabl
import
protein
translat
close
regul
prevent
malign
transform
cancer
develop
translat
control
rather
initi
even
though
control
elong
phase
activ
control
sever
mechan
describ
van
der
kelen
et
al
although
well
studi
role
translat
initi
involv
tumorigenesi
littl
known
express
regul
surprisingli
overexpress
lead
global
increas
protein
translat
lead
select
increas
translat
mrna
structur
call
sensibl
element
involv
tumorigenesi
studi
show
inhibit
lead
hela
cancer
cell
death
absenc
lethal
saccharomyc
cerevisia
overexpress
act
like
oncogen
promot
malign
transform
lymphomagenesi
rodent
cell
overproduct
caus
uncontrol
cell
growth
oncogenesi
indic
import
protein
synthesi
andrieu
et
al
given
import
function
protein
surpris
find
activ
highli
regul
serum
growth
factor
immunolog
activ
lymphocyt
lead
increas
gene
transcript
schmidt
also
consensu
bind
site
transcript
factor
cmyc
hnrnpk
involv
control
gene
transcript
respons
stimuli
lynch
et
al
exampl
least
seven
phosphoryl
site
among
four
known
regul
signal
pathway
mtor
gingra
raught
sonenberg
heesom
et
al
wang
et
al
cmyc
overexpress
due
growth
factor
express
rise
mammal
phosphoryl
serin
residu
locat
ctermin
motif
conserv
speci
except
plant
cerevisia
kinas
mapkintegr
kinas
ueda
et
al
bind
ctermin
end
close
phosphoryl
kinas
activ
phosphoryl
realiz
erk
kinas
extracellular
signalregul
kinas
map
kinas
fig
scheper
et
al
growth
factor
phorbol
ester
insulin
activ
mnk
kinas
via
erk
pathway
tschopp
et
al
cytokin
stress
condit
activ
map
kinas
pathway
phosphoryl
also
regul
viral
infect
exampl
adenoviru
infect
dephosphoryl
viral
protein
bind
move
mnk
kinas
complex
phenomenon
observ
influenza
viru
infect
cuesta
xi
schneider
howev
coronaviru
infect
activ
increas
phosphoryl
via
map
kinas
pathway
banerje
et
al
although
phosphoryl
mechan
known
consequ
phosphoryl
translat
initi
still
unclear
depend
cellular
context
scheper
proud
modul
interact
phosphoryl
control
bind
control
mapkmedi
phosphoryl
activ
site
furthermor
absenc
mapk
signal
phosphoryl
prevent
ctermin
domain
restrict
interact
shveygert
et
al
protein
famili
regul
capac
form
capbind
complex
current
three
known
mammal
interact
strength
regul
phosphoryl
phosphoryl
respons
growth
factor
amino
acid
hormon
insulin
activ
mtor
pathway
molecular
target
rapamycin
fig
gingra
et
al
gingra
raught
sonenberg
kimbal
exampl
least
seven
phosphoryl
site
among
four
known
regul
signal
pathway
mtor
gingra
et
al
heesom
et
al
wang
et
al
contrast
hypoxia
induc
phosphoryl
decreas
shenberg
et
al
hypophosphoryl
sequestr
also
consensu
bind
site
transcript
factor
cmyc
hnrnpk
involv
control
gene
transcript
respons
stimuli
cmyc
overexpress
express
rise
overexpress
lead
select
increas
translat
mrna
structur
call
sensibl
element
involv
tumorigenesi
prevent
interact
inhibit
translat
hyperphosphoryl
bind
releas
particip
protein
translat
initi
fig
gingra
et
al
protein
bind
site
competit
protein
hand
bond
prevent
bond
cap
otherwis
virus
modul
activ
act
phosphoryl
exampl
picornavirus
induc
dephosphoryl
inhibit
protein
synthesi
work
inhibitor
capdepend
translat
figur
implic
mrna
translat
initi
translat
initi
mrna
occur
due
capdepend
mechan
involv
mechan
regul
phosphoryl
mnk
protein
well
factor
activ
repressor
role
phosphoryl
translat
anoth
posttransl
modif
ubiquitin
demonstr
prevent
mrna
cap
bind
prevent
bond
thu
phosphoryl
reduc
murata
shimotohno
othumpangat
kashon
joseph
howev
ubiquitin
consequ
translat
initi
still
unknown
degrad
depend
proteasom
happen
princip
ligas
chip
ubiquitin
residu
murata
shimotohno
othumpangat
et
al
ubiquitin
prevent
bond
mrna
cap
bond
phosphoryl
reduc
moreov
interact
directli
regul
knockdown
ubiquitin
degrad
ubiquitinproteasom
pathway
indic
cytoprotect
induc
involv
andrieu
et
al
show
castrateresist
prostat
cancer
forc
overexpress
increas
protein
express
level
without
affect
mrna
express
level
also
show
could
exert
effect
directli
effect
level
independ
show
decreas
ubiquitin
associ
resist
androgen
withdraw
paclitaxel
conclud
knockdown
reduc
stabil
enhanc
ubiquitin
degrad
therebi
reduc
cell
viabil
androgen
withdraw
andor
chemotherapi
andrieu
et
al
pancreat
cancer
cell
baylot
et
al
demonstr
ctermin
part
interact
phosphoryl
enhanc
interact
express
level
gemcitabin
resist
enhanc
protein
express
induc
decreas
approxim
amount
ubiquitin
therebi
inhibit
proteasom
degrad
baylot
et
al
also
describ
protein
iap
famili
inhibitor
apoptosi
protein
interact
lead
ubiquitin
lee
et
al
new
translat
repress
mechan
specif
mrna
describ
richter
sonenberg
xenopu
laevi
oocyt
develop
translat
regul
mechan
base
length
polya
tail
dormant
stabl
mrna
short
polya
tail
unlik
major
mrna
long
tail
cpeb
protein
control
polyadenyl
interact
cpe
element
mrna
extrem
cpeb
also
bind
maskin
protein
sequestr
prevent
translat
specif
mrna
oocyt
stimul
signal
cascad
take
place
allow
polya
tail
elong
cpeb
maskin
protein
move
translat
start
similar
mechan
observ
drosophila
bicoid
cup
protein
nakamura
sato
hanyunakamura
niess
blank
jackl
neurogenesi
neuroguidin
protein
bind
prevent
translat
jung
lorenz
richter
two
type
mrna
translat
initi
capdepend
translat
initi
capindepend
translat
initi
furthermor
anoth
mrna
categori
translat
capand
manner
mrna
structur
call
ire
intern
ribosom
entri
site
allow
ribosom
subunit
bind
directli
origin
identifi
translat
mechan
viral
gene
identifi
play
import
role
death
cell
process
mitosi
stress
condit
capdepend
protein
synthesi
reduc
stoneley
willi
translat
initi
cellular
mrna
take
place
due
capdepend
mechan
structur
also
call
cap
locat
extrem
cytoplasm
mrna
process
capdepend
translat
process
posttranscript
modif
introduc
success
action
sever
nuclear
enzym
cap
mani
role
protect
mrna
degrad
ribonucleas
interven
nuclear
export
allow
ribosom
recruit
fact
structur
specif
recogn
enabl
recruit
complex
bind
cap
fig
complex
form
associ
allow
recruit
ribosom
mrna
protein
helicas
catalyz
separ
pair
strand
rna
atpdepend
manner
activ
slow
requir
stimul
roger
komar
merrick
protein
act
like
scaffold
protein
link
mrna
subunit
ribosom
interact
stabil
complex
gross
et
al
prevot
darlix
ohlmann
step
lead
recruit
preiniti
complex
mrna
cap
format
initi
complex
arnm
fig
mrna
scan
direct
order
find
start
codon
kozak
due
follow
initi
factor
complex
initi
codon
locat
interact
promot
intrins
hydrolysi
gtp
associ
hydrolysi
lead
detach
initi
factor
ribosom
subunit
recruit
subunit
result
format
complex
fig
protein
synthesi
begin
utr
extrem
untransl
region
also
play
import
role
translat
initi
mechan
fact
extrem
sequenc
surround
start
codon
play
role
initi
site
select
complex
give
indic
translat
effici
might
weak
strong
mammal
kozak
sequenc
best
sequenc
initi
translat
extrem
polya
tail
capabl
interact
cap
pabp
polyadenylatebind
protein
fig
interact
promot
ribosom
subunit
recruit
direct
interact
pabp
interact
give
circular
conform
mrna
improv
translat
initi
protein
play
major
role
mrna
capdepend
translat
regul
sonenberg
therefor
cell
cycl
progress
ofarrel
note
mode
translat
initi
describ
protein
exampl
involv
translat
viral
mrna
cap
fact
recent
demonstr
caliciviru
mrna
link
coval
viral
protein
vpg
act
like
substitut
cap
recruit
chaudhri
et
al
vpgbind
site
differ
capbind
site
protein
bind
site
sinc
complex
isol
goodfellow
et
al
interact
uniqu
within
known
viru
mammal
find
similar
interact
potyviru
infect
plant
dreher
miller
describ
mainli
locat
cytoplasm
fulfil
role
translat
initi
also
found
nucleu
recent
describ
function
regul
translat
differ
level
initi
strudwick
borden
lejbkowicz
et
al
first
one
describ
express
nucleu
small
structur
call
nuclear
bodi
fig
b
observ
varieti
mammalian
cell
line
would
conserv
among
eukaryot
find
nuclear
bodi
per
nucleu
size
vari
cohen
et
al
dosti
lejbkowicz
sonenberg
lai
borden
bodi
affect
rnase
dnase
indic
structur
form
nucleic
acid
cohen
et
al
dosti
et
al
export
nucleu
via
importin
activ
pathway
involv
protein
bind
similar
region
dosti
et
al
protein
found
nuclear
bodi
involv
export
mrna
categori
nucleu
cytoplasm
culjkov
topisirov
borden
mrna
categori
structur
call
sensibl
element
allow
recogn
mrna
fig
culjkov
et
al
normal
mrna
prepar
export
process
regul
nuclear
complex
cbc
capbind
complex
categori
mrna
nuclear
bodi
abl
regul
transport
cohen
et
al
lai
borden
mrna
sensit
also
long
complex
utr
end
hardli
decondens
helicas
zimmer
debenedetti
graff
theoret
sinc
limit
factor
helicas
recruit
increas
rise
helicas
activ
thu
increas
specif
mrna
protein
synthesi
zimmer
et
al
howev
mrna
sensit
show
increas
translat
initi
rate
mrna
protein
synthesi
regul
export
nucleu
cytoplasm
lai
borden
inde
overexpress
cyclin
mrna
level
chang
level
nuclear
mrna
decreas
level
cytoplasm
mrna
increas
result
show
increas
express
increas
export
mrna
thu
level
protein
lai
borden
export
mechan
contribut
oncogen
potenti
cohen
et
al
therefor
possibl
nucleu
neg
regul
process
ident
cytoplasm
sever
protein
associ
nuclear
bodi
ribosom
protein
p
iborra
jackson
cook
prh
protein
prolinerich
homeodomain
protein
topisirov
et
al
homeodomain
protein
z
protein
pml
protein
studi
campbel
dwyer
et
al
cohen
et
al
lai
borden
protein
regul
bond
bond
necessari
mrna
export
dosti
et
al
major
nuclear
protein
coloc
pml
protein
lai
borden
result
stress
viral
infect
interferon
treatment
regad
chelbialix
protein
interact
convex
side
ring
domain
use
tryptophan
residu
cohen
et
al
lai
borden
even
though
interact
site
far
capbind
site
bond
inhibit
interact
culjkov
et
al
pml
protein
bind
lower
mrna
cap
affin
time
therebi
chang
mrna
export
function
fig
cohen
et
al
culjkov
et
al
kentsi
et
al
lai
borden
pml
would
antitumor
function
approxim
homeodomain
protein
contain
potenti
bind
site
could
therefor
regul
culjkov
et
al
seem
abil
modul
activ
act
bind
cap
conserv
cytoplasm
nucleu
final
suggest
contribut
mrna
translat
nucleu
dosti
et
al
iborra
et
al
nuclear
translat
phenomenon
alreadi
observ
mammal
cell
iborra
et
al
increas
number
protein
translat
machineri
involv
nuclear
process
translat
may
involv
aberr
transcript
elimin
mrna
qualiti
control
system
nmd
nonsensemedi
decay
inde
system
requir
activ
protein
synthesi
order
detect
appear
prematur
stop
codon
lead
synthesi
truncat
protein
known
data
role
translat
initi
nuclear
export
led
hypothesi
regulon
culjkov
et
al
regulon
set
gene
regul
protein
hypothesi
suggest
mrna
belong
regulon
signal
allow
recruit
protein
consid
regulatori
sinc
allow
one
hand
nuclear
export
site
recognit
hand
protein
translat
anoth
unknown
signal
case
act
mechan
like
due
presenc
signal
protein
thu
orchestr
gene
express
control
cell
cycl
progress
protein
synthesi
highli
regul
process
control
mrna
translat
alter
process
associ
develop
progress
cancer
describ
compon
translat
machineri
regul
sever
fundament
signal
pathway
often
disrupt
cancer
thu
protein
translat
process
becom
oncogen
sonenberg
et
al
first
show
involv
oncogenesi
sinc
oncogen
potenti
due
hyperact
wide
describ
vitro
vivo
overexpress
induc
primari
epitheli
cell
fibroblast
transform
similarli
extend
overexpress
nih
cho
cell
line
lead
oncogen
transform
metastat
phenotyp
avdulov
et
al
de
benedetti
graff
zimmer
et
al
vivo
overexpress
lead
lymphoma
angiosarcoma
lung
carcinoma
develop
transgen
mice
ruggero
et
al
addit
describ
capabl
increas
cellular
prolifer
inhibit
apoptosi
li
et
al
ruggero
et
al
wendel
et
al
act
surviv
factor
serumdepriv
cell
cell
whose
ra
cmyc
oncogen
express
deregul
li
et
al
polunovski
et
al
tan
et
al
upstream
signal
pathway
mutat
amplifi
cancer
direct
impact
activ
exampl
promot
contain
two
domain
oncogen
cmyc
target
mtor
pathway
activ
occur
mani
cancer
also
allow
phosphoryl
consequ
hyperactiv
hyperphosphoryl
also
associ
malign
progress
breast
ovarian
prostat
colon
cancer
armengol
et
al
coleman
et
al
graff
et
al
final
level
increas
observ
follow
human
tumor
breast
bladder
colon
lung
skin
head
neck
ovarian
prostat
cancer
compar
healthi
tissu
berkel
et
al
coleman
et
al
crew
et
al
graff
et
al
holm
et
al
matthewsgr
et
al
nathan
et
al
salehi
mashayekhi
shahosseini
thumma
kratzk
wang
et
al
although
high
express
level
seem
correl
aggress
metastat
tumor
protein
given
diagnost
marker
cancer
berkel
et
al
de
benedetti
graff
defatta
li
de
benedetti
li
et
al
found
aggress
cancer
yang
et
al
breast
cancer
shown
patient
therapi
low
level
better
surviv
rate
hiller
et
al
howev
high
level
higher
risk
recurr
holm
et
al
overexpress
also
lead
protein
overexpress
induc
resist
doxorubicin
treatment
well
radiotherapi
li
et
al
sillj
nigg
prostat
cancer
immunohistochemistri
studi
tissu
show
phosphoryl
form
express
significantli
increas
advanc
prostat
cancer
compar
benign
hyperplasia
graff
et
al
addit
shown
phosphoryl
requir
translat
sever
protein
involv
tumorigenesi
furthermor
phosphoryl
level
correl
pancrea
prostat
cancer
progress
baylot
et
al
bianchini
et
al
furic
et
al
moreov
previous
show
knockdown
lead
ubiquitin
degrad
ubiquitinproteasom
pathway
decreas
ubiquitin
degrad
associ
resist
androgen
withdraw
paclitaxel
prostat
cancer
gemcitabin
pancreat
cancer
andrieu
et
al
baylot
et
al
vivo
studi
show
block
hyperact
inhibit
mtor
pathway
caus
inhibit
tumor
growth
format
transgen
mous
model
develop
thymu
lymphoma
hsieh
et
al
work
demonstr
oncogen
potenti
interest
therapeut
target
protein
activ
exact
mechan
complex
induc
oncogen
transform
highli
debat
describ
may
partli
mediat
mrna
subset
translat
increas
rather
overal
increas
translat
rate
fig
classif
regress
tree
cart
divid
mrna
accord
utr
end
davuluri
et
al
vast
major
mrna
short
unstructur
utr
end
strongli
translat
mrna
encod
housekeep
protein
howev
also
mrna
whose
utr
end
long
structur
rich
gc
nucleic
acid
poorli
translat
normal
cellular
condit
utr
end
prevent
effect
activ
bind
ribosom
second
categori
mrna
encod
protein
import
role
oncogenesi
thu
protein
involv
prolifer
cyclin
cmyc
apoptosi
survivin
angiogenesi
vegf
metastasi
heparanas
maman
et
al
schmidt
zimmer
et
al
given
limit
factor
translat
initi
mechan
mrna
compet
normal
cellular
condit
howev
level
increas
like
cancer
mrna
poorli
translat
select
translat
disproportion
fig
de
benedetti
graff
graff
et
al
maman
et
al
thu
factor
govern
cancer
progress
coordin
certain
gene
express
avdulov
et
al
addit
describ
overexpress
increas
specif
mrna
sensit
transport
translat
topisirov
et
al
mrna
encod
protein
involv
cell
prolifer
tumorigenesi
cyclin
transport
mechan
would
therefor
contribut
oncogen
potenti
cohen
et
al
due
import
involv
process
tumorigenesi
sever
inhibitori
strategi
develop
block
function
cellular
mrna
divid
two
categori
major
mrna
highli
translat
even
express
limit
minor
mrna
weakli
translat
translat
overexpress
like
cancer
develop
second
categori
includ
gene
involv
tumorigenesi
adapt
graff
et
al
first
strategi
develop
antisens
oligonucleotid
aso
block
mrna
translat
thu
defatta
et
al
shown
translat
inhibit
aso
elimin
tumorigen
angiogen
properti
fadu
human
squamou
carcinoma
cell
defatta
nathan
de
benedetti
recent
secondgener
aso
design
graff
et
al
resist
nucleas
fig
graff
et
al
nanomolar
concentr
figur
inhibitor
diagram
show
differ
strategi
inhibit
cancer
therapi
inhibit
product
aso
eg
inhibit
interact
ligand
inhibitori
molecul
eg
b
inhibit
interact
mrna
cap
analog
eg
ribavirin
c
abl
reduc
level
thu
induc
apoptosi
sever
cancer
cell
line
vitro
vivo
model
breast
cancer
significantli
inhibit
tumor
growth
without
side
effect
weight
loss
express
reduc
observ
tissu
moreov
similar
result
observ
prostat
cancer
xenograft
treatment
graff
et
al
hand
sirna
target
recent
describ
abil
inhibit
tumor
growth
induc
apoptosi
enhanc
effect
chemotherapi
cisplatin
breast
carcinoma
vitro
vivo
dong
et
al
prostat
cancer
model
vivo
knockdown
use
sirna
revers
cytoprotect
androgen
withdraw
serumfre
media
paclitaxel
treatment
normal
confer
overexpress
moreov
overexpress
confer
resist
combin
treatment
paclitaxel
androgen
withdraw
lncap
cell
andrieu
et
al
anoth
strategi
inhibit
eukaryot
factor
target
interact
prevent
format
complex
lead
inhibit
capdepend
translat
exampl
peptid
abl
disrupt
interact
develop
peptid
describ
induc
apoptosi
lung
cell
dosedepend
manner
herbert
et
al
recent
highthroughput
screen
perform
identifi
inhibitor
interact
compound
identifi
hit
bind
block
interact
moerk
et
al
although
share
interact
site
seem
take
larger
space
block
interact
even
report
increas
interact
result
inhibit
capdepend
translat
fig
compound
shown
reduc
cmyc
level
induc
apoptosi
inhibit
lung
cancer
cell
prolifer
fan
et
al
would
interest
know
compound
specif
inhibit
interact
determin
proteinprotein
interact
signal
pathway
block
fact
studi
shown
induc
apoptosi
interactionindepend
mechan
degrad
antiapoptot
protein
cflip
fan
et
al
recent
compound
character
inhibitor
interact
fig
cencic
et
al
report
compound
may
partial
inhibit
capdepend
translat
restor
chemosensit
lymphoma
mous
model
anoth
compound
screen
inhibit
capdepend
translat
coronaviru
replic
depend
complex
cencic
et
al
anoth
strategi
base
inhibit
synthesi
mrna
cap
analog
would
compet
interact
block
quiocho
hu
gershon
seri
cap
analog
develop
brown
et
al
ghosh
et
al
ghosh
et
al
kowalska
et
al
ribavirin
current
use
fig
inde
use
analog
drug
difficult
low
membran
permeabl
due
natur
extrem
charg
phosphat
group
metabol
labil
due
instabl
glycosid
bond
ribavirin
broadspectrum
antivir
drug
use
treatment
hepat
c
similar
ribavirin
structur
mrna
cap
suggest
drug
act
inhibitor
mimick
cap
later
studi
show
ribavirin
interact
prevent
bind
mrna
cap
inhibit
capdepend
translat
cell
transform
kentsi
et
al
kentsi
et
al
tan
et
al
howev
question
aris
specif
action
ribavirin
studi
controversi
westman
et
al
yan
et
al
nevertheless
molecul
current
clinic
trial
phase
ii
treatment
acut
myeloid
leukemia
first
clinic
result
show
stabil
least
partial
cure
patient
assoulin
et
al
studi
first
show
capdepend
translat
inhibit
clinic
util
cancer
overexpress
borden
culjkovickraljac
mention
earlier
signal
pathway
upstream
also
involv
tumorigenesi
repres
therapeut
target
thu
sever
inhibitor
develop
target
compon
indirectli
mnk
kinas
inhibitor
cercosporamid
mtor
pathway
inhibitor
rapamycin
temsirolimu
etc
choo
et
al
feldman
et
al
garciamartinez
et
al
konicek
et
al
yu
et
al
temsirolimu
approv
fda
treatment
patient
advanc
renalcel
cancer
trial
demonstr
significantli
outperform
standard
care
term
progressionfre
surviv
overal
surviv
month
respect
furthermor
preclin
evalu
two
torkinib
secondgener
smallmolecul
inhibitor
demonstr
stronger
inhibit
protein
synthesi
cell
prolifer
sirolimu
blagden
willi
recent
target
interact
describ
interest
altern
strategi
target
previous
found
interact
directli
eukaryot
translat
initi
factor
work
demonstr
interact
protect
degrad
ubiquitinproteasom
pathway
lead
cytoprotect
pancrea
crpc
andrieu
et
al
baylot
et
al
use
sever
delet
mutant
found
interact
ctermin
domain
inhibit
interact
use
delet
mutant
drive
resist
apoptosi
induc
gemcitabin
pancreat
cancer
baylot
et
al
androgen
withdraw
docetaxel
castrateresist
prostat
cancer
unpublish
data
experi
confirm
stressinduc
cellular
pathway
involv
cell
death
blockad
lead
therapi
resist
cancer
target
interact
seem
promis
therapeut
strategi
advanc
prostat
pancreat
cancer
tumorigenesi
highli
affect
regul
capdepend
translat
capdepend
translat
consist
eukaryot
translat
initi
factor
complex
recogn
end
cellular
mrna
cap
structur
compon
complex
make
crucial
capdepend
translat
initi
regul
tumor
cell
apoptosi
prolifer
potenti
metastasi
inde
sinc
inhibit
induc
cellular
death
entitl
ask
inhibit
consequ
normal
cell
seem
howev
residu
low
level
drug
treatment
toler
without
advers
effect
normal
tissu
contrast
activ
import
cancer
cell
inhibit
visibl
effect
graff
et
al
mani
approach
year
use
tri
inhibit
function
particularli
use
smallmolecul
inhibitor
disrupt
interact
use
cap
analog
directli
target
capbind
site
aso
prove
effici
reduc
express
level
advanc
clinic
trial
prostat
cancer
patient
recent
target
interact
describ
interest
altern
strategi
target
taken
togeth
data
seem
show
promis
target
cancer
therapi
new
approach
inhibit
deserv
studi
